Clinical trial
A Multi-cohort, Randomized, Phase 2, Open-label Study to Assess the Preliminary Efficacy, Safety, and Pharmacokinetics of BIVV020 for Prevention and Treatment of Antibody-mediated Rejection in Adult Kidney Transplant Recipients.
NCT05156710 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multi-cohort, Randomized, Phase 2, Open-label Study to Assess the Preliminary Efficacy, Safety, and Pharmacokinetics of BIVV020 for Prevention and Treatment of Antibody-mediated Rejection in Adult Kidney Transplant Recipients.
- Lead sponsor
- Sanofi
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- June 9, 2022
- Completion date
- October 20, 2026
- Enrollment
- 48 (actual)
- Sites
- 27
Conditions
As the registry lists them; a condition with its own page is linked.
transplant rejection